{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:39:42Z","timestamp":1765438782358,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["17JCZDJC33100"],"award-info":[{"award-number":["17JCZDJC33100"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977080","21371135"],"award-info":[{"award-number":["21977080","21371135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Inorganic Biochemistry"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jinorgbio.2022.111842","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:33:07Z","timestamp":1650479587000},"page":"111842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy"],"prefix":"10.1016","volume":"232","author":[{"given":"Zhe","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Zhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinorgbio.2022.111842_bb0005","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for Cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00264","article-title":"Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung Cancer: a systematic review and literature-based Meta-analysis","volume":"9","author":"Addeo","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0015","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0020","first-page":"S8","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis, Transl. Lung","volume":"6","author":"Hu","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0025","article-title":"Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)","volume":"7","author":"Marius","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0030","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1002\/jcp.29671","article-title":"Role of tumor microenvironment in the regulation of PD-L1: a novel role in resistance to cancer immunotherapy","volume":"235","author":"Khandani","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0040","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/mc.22881","article-title":"Epidermal growth factor induces STAT1 expression to exacerbate the IFN\u03b3-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers","volume":"57","author":"Cheng","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0045","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423170","article-title":"PD-L1 expression is regulated by both DNA methylation and NF-\u03baB during EMT signaling in non-small cell lung carcinoma","volume":"7","author":"Asgarova","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2019.01.004","article-title":"PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data","volume":"129","author":"Koh","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.201040979","article-title":"PD-L1 expression on tolerogenic APCs is controlled by STAT-3","volume":"41","author":"W\u00f6lfle","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02129","article-title":"Interferon-\u03b1 up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling","volume":"9","author":"Bazhin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0070","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0075","first-page":"691","article-title":"Thalidomide and congenital abnormalities","volume":"279","author":"Speirs","year":"1962","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1267\/ahc.10030","article-title":"Thalidomide prevents the progression of peritoneal fibrosis in mice","volume":"44","author":"Arai","year":"2011","journal-title":"Acta Histochem. Cytochem."},{"issue":"Suppl. 3","key":"10.1016\/j.jinorgbio.2022.111842_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in Cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4065\/79.7.875","article-title":"Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity","volume":"79","author":"Richardson","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109652","article-title":"Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1\/miR-454-3p\/ZEB1 axis-mediated VEGFA expression and PD-1\/PD-L1 checkpoint in NSCLC","volume":"349","author":"Xia","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/onc.2011.238","article-title":"\u03b2-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression","volume":"31","author":"Shenoy","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0110","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-18-1781","article-title":"Pomalidomide inhibits PD-L1 to promote anti-tumor immunity","author":"Fujiwara","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920923829","article-title":"Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients","volume":"12","author":"Sun","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0120","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.14763","article-title":"The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers","volume":"178","author":"Li","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0130","first-page":"589","article-title":"Possible mechanisms for the antitumor activity of platinum coordination complexes","volume":"59","author":"Rosenberg","year":"1975","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0140","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1039\/c3cc48740g","article-title":"Conjugation of vitamin E analog \u03b1-TOS to Pt(IV) complexes for dual-targeting anticancer therapy","volume":"50","author":"Suntharalingam","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0145","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.addr.2012.01.007","article-title":"Redox activation of metal-based prodrugs as a strategy for drug delivery","volume":"64","author":"Graf","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0150","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1039\/C9DT04594E","article-title":"Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity","volume":"49","author":"Tan","year":"2020","journal-title":"Dalton Trans."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0155","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast Cancer: the first clinical evidences are emerging\u2014a literature review","volume":"11","author":"Planes-Laine","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0160","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0968-0896(00)00342-4","article-title":"Synthesis and immunological activity of water-soluble thalidomide prodrugs","volume":"9","author":"Hess","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0165","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2174\/0929867054637626","article-title":"Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches","volume":"12","author":"Galanski","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0170","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1182\/blood-2006-04-017046","article-title":"Selective leukemic-cell killing by a novel functional class of thalidomide analogs","volume":"108","author":"Ge","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0175","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/ja5038269","article-title":"Pt(IV) Prodrugs designed to bind non-covalently to human serum albumin for drug delivery","volume":"136","author":"Zheng","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"56","key":"10.1016\/j.jinorgbio.2022.111842_bb0180","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1038\/sj.onc.1207230","article-title":"To be, or not to be: NF-kappaB is the answer--role of Rel\/NF-kappaB in the regulation of apoptosis","volume":"22","author":"Kucharczak","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-2952(98)00224-X","article-title":"Uckun. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target","author":"Waddick","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.jinorgbio.2022.111842_bb0190","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00018-020-03677-7","article-title":"Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies","volume":"78","author":"Orazi","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423170","article-title":"PD-L1 expression is regulated by both DNA methylation and NF-\u03baB during EMT signaling in non-small cell lung carcinoma","volume":"7","author":"Asgarova","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0200","first-page":"945","article-title":"Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention","volume":"8","author":"Buettner","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcp.10364","article-title":"STAT proteins: from normal control of cellular events to tumorigenesis","volume":"197","author":"Calo","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0215","first-page":"402","article-title":"The effect of (\u2212)-Epigallocatechin-3-gallate (EGCG) on the expression of HIF-1\u03b1 and VEGF in breast cancer MCF-7 cells","volume":"18","author":"Fu","year":"2012","journal-title":"J .chi. on. col."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0220","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.seminoncol.2015.02.009","article-title":"Immune response regulation in the tumor microenvironment by hypoxia","volume":"42","author":"Labiano","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2019.01.004","article-title":"PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data","volume":"129","author":"Koh","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jinorgbio.2022.111842_bb0230","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."}],"container-title":["Journal of Inorganic Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013422001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0162013422001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:07:40Z","timestamp":1758985660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0162013422001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":46,"alternative-id":["S0162013422001313"],"URL":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2022.111842","relation":{},"ISSN":["0162-0134"],"issn-type":[{"type":"print","value":"0162-0134"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Inorganic Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinorgbio.2022.111842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111842"}}